title: [Indications for the use of continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus].
abstract: BACKGROUND
  Diabetes is a serious health problem for pediatrics. In pediatric patients control depends on correct insulin administration. The most usual is subcutaneous administration according to the glycemic control. The aim was to analyze the indications for continuous subcutaneous insulin infusion (CSII) in type 1 diabetes mellitus (T1DM) children and adolescents.
  
  
  METHODS
  It was carried out a descriptive study in patients from 1 to 16 years with T1DM who underwent CSII therapy. The main cause to use this therapy was analyzed, and also if that cause was different regarding age, sex and disease progression.
  
  
  RESULTS
  61 patients underwent CSII therapy. The median age at the beginning of treatment was 9 years old; 43 patients (71.6 %) had more than one year of diagnosis. The main reasons to use CSII were: 42.6 % had to improve their quality of life, 34.4 % had to reduce the high glycemic variability, 13.1 % had to control severe recurrent hypoglycemia, and 9.8 % had to control their HbA1c. For children under 6 years of age (n = 14) the more frequent indication were recurrent hypoglycemia and to improve their quality of life; children from 6 to 12 years of age (n = 27) had to improve their quality of life, and in children over 12 years CSII was indicated for high glycemic variability and severe recurrent hypoglycemia. There was no different indication related between sexes.
  
  
  CONCLUSIONS
  Improve their quality of life and reach a better glycemic control were the main reasons to start CSII in our patients.
authors.affiliation: Facultad Mexicana de Medicina, Universidad La Salle, Distrito Federal, México. mario.rendon@imss.gob.mx.
authors.forename: Diana
authors.initials: D
authors.lastname: Espejel-Huerta
authors.forename: Carlos Alberto
authors.initials: CA
authors.lastname: Antillón-Ferreira
authors.forename: José
authors.initials: J
authors.lastname: Iglesias-Leboreiro
authors.forename: Isabel
authors.initials: I
authors.lastname: Bernárdez-Zapata
authors.forename: Angélica
authors.initials: A
authors.lastname: Martínez-Ramos Méndez
authors.forename: Mario Enrique
authors.initials: ME
authors.lastname: Rendón-Macías
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D000066491:Clinical Decision-Making; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007223:Infant; D015918:Infusion Pumps, Implantable; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008297:Male; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin
keywords: Diabetes mellitus; Glycosylated hemoglobin A; Insulin infusion systems